Search

Your search keyword '"Porteus, Matthew H"' showing total 608 results

Search Constraints

Start Over You searched for: Author "Porteus, Matthew H" Remove constraint Author: "Porteus, Matthew H"
608 results on '"Porteus, Matthew H"'

Search Results

103. High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia

113. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease

115. Highly Efficient Repair of the ΔF508 Mutation in Airway Stem Cells of Cystic Fibrosis Patients with Functional Rescue of the Differentiated Epithelia

116. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements

118. Small-molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states

119. Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells

121. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification

123. Gene Correction for SCID-X1 in Long-Term Hematopoietic Stem Cells

127. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells

128. Genome Editing Technologies: Defining a Path to Clinic

129. Correction of X-CGD patient HSPCs by targeted CYBBcDNA insertion using CRISPR/Cas9 with 53BP1 inhibition for enhanced homology-directed repair

130. Neuronal defects in a human cellular model of 22q11.2 deletion syndrome

134. A Comprehensive TALEN-Based Knockout Library for Generating Human-Induced Pluripotent Stem Cell–Based Models for Cardiovascular Diseases

135. Abstract 100

136. Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)—The Primary Immune Deficiency Treatment Consortium (PIDTC)

137. Anti-Fungal Prophylaxis Using Intermediate Dose Ambisome is Associated with Delayed Methotrexate Clearance in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

138. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

139. Genome Editing Technologies: Defining a Path to Clinic: Genomic Editing: Establishing Preclinical Toxicology Standards, Bethesda, Maryland 10 June 2014

140. Genetically corrected RAG2-SCID human hematopoietic stem cells restore V(D)J-recombinase and rescue lymphoid deficiency

142. 43. CRISPR/Cas9 and rAAV6-Mediated Targeted Integration at the CCR5 Locus in Hematopoietic Stem and Progenitor Cells

143. 39. FACS-Based Enrichment of a Highly Purified HBB-Targeted Hematopoietic Stem and Progenitor Cell Population Using rAAV6 and CRISPR/Cas9

146. Initial Results from Stanford Children’s Fanconi Anemia Clinical Trial Using JSP191 Antibody Conditioning and TCRαβ+T-Cell/CD19+B-Cell Depleted Grafts

148. Identification of preexisting adaptive immunity to Cas9 proteins in humans

149. Zinc fingers on target: the existing methods of creating genetically modified plants are inefficient and imprecise. Zinc-finger technology offers the prospect of opening up a swifter and more exact route for crop improvement

Catalog

Books, media, physical & digital resources